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Background: This study describes early treatment drug use status and associated clinical characteristics in a diverse
sample of patients entering outpatient substance abuse psychosocial counseling treatment. The goal is to more
fully characterize those entering treatment with and without active use of their primary drug in order to better
understand associated treatment needs and resilience factors.
Methods: We examined baseline data from a NIDA Clinical Trials Network (CTN) study (Web-delivery of Treatment
for Substance Use) with an all-comers sample of patients (N = 494) entering 10 outpatient treatment centers.
Patients were categorized according to self-identified primary drug of abuse (alcohol, cocaine/stimulants, opioids,
marijuana) and by baseline drug use status (positive/negative) based on urine testing or self-reports of recent use
(alcohol). Characteristics were examined by primary drug and early use status.
Results: Classified as drug-negative were 84%, 76%, 62%, and 33% of primary opioid, stimulant, alcohol, and
marijuana users; respectively. Drug-positive versus -negative patients did not differ on demographics or rates of
substance abuse/dependence diagnoses. However, those negative for active use had better physical and mental
health profiles, were less likely to be using a secondary drug, and were more likely to be attending 12-step self-help
meetings.
Conclusions: Early treatment drug abstinence is common among substance users entering outpatient psychosocial
counseling programs, regardless of primary abused drug. Abstinence (by negative UA) is associated with better
health and mental health profiles, less secondary drug use, and more days of 12-step attendance. These data
highlight differential treatment needs and resiliencies associated with early treatment drug use status.
Trial registration: NCT01104805.
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Outpatient substance abuse treatment programs that
offer psychosocial counseling as the primary care modal-
ity enroll individuals who present for treatment with a
wide range of drug use profiles. Prominent among these
individual differences are the drug(s) endorsed as the
primary problem, and reason for treatment entry, and
the current drug use status of the individuals entering
treatment. In clinical trials with stimulant abusers, it re-
peatedly has been shown that a substantial proportion
has already achieved abstinence prior to treatment entry* Correspondence: gcochran@pitt.edu
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unless otherwise stated.or does so rapidly upon treatment entry, and that early
drug abstinence is strongly associated with better treatment
prognosis [1-16]. Studies among alcohol users receiving
treatment similarly have described divergent pre-treatment
drinking patterns, including pre-treatment abstinence, and
have demonstrated their association with treatment out-
comes [17,18]. However, these studies infrequently report
the physical, mental health, and behavioral characteristics
of individuals entering treatment as a function of either
current drug use status or primary drug problem. Given
the major emphasis in health-care reform regarding the
identification and treatment of co-occurring health, mental
health, and substance use disorders [19,20], it is critical to
expand current knowledge in the field regarding baseline
health and behavioral health profiles of individuals enteringl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fashion.
A recently completed study within the National Institute
on Drug Abuse Treatment Clinical Trials Network (NIDA
CTN 0044; WEB-TX) enrolled a large “all-comers” sample
of substance users seeking treatment at 10 regionally di-
verse outpatient psychosocial counseling programs for an
array of specific primary substance use problems; including
problems associated with alcohol, cocaine/stimulants, opi-
oids, marijuana. This large and diverse sample provides the
opportunity to obtain a comprehensive profile of pre- and
early-treatment behavioral health, substance use, and be-
havioral resilience factors among a large and diverse sample
of substance users and to relate these variables to drug use
status (active-use versus abstinence) shortly after treatment
entry. Such information has the potential to inform pro-
viders about patients’ needs and challenges when initiating
treatment in order to better tailor care for those needs.
Methods
Participants and recruitment procedures
Methods of this CTN clinical trial have been described in
detail elsewhere [21]. Here, we present a brief overview
with emphasis on methods relevant to the current second-
ary analysis of baseline data. Individuals seeking substance
abuse treatment at 10 regionally diverse outpatient treat-
ment centers across the US were given information on the
WEB-TX study at treatment entry and, if interested, were
referred to research staff members at the treatment pro-
gram. After providing verbal consent, potential partici-
pants were assessed for eligibility via a short screening
instrument. If the participant was eligible, a baseline as-
sessment was scheduled. Before completing the baseline
assessment, patients provided written informed consent.
The study was designed to maximize participant hetero-
geneity and recruit all-comers seeking substance abuse
treatment; thus, eligibility was kept purposefully broad.
Eligible participants: 1) were 18 years of age or older; 2)
had self-reported a substance use problem and illicit sub-
stance use in the 30 days prior to baseline assessment (or
60 days if the participant was exiting a controlled environ-
ment); 3) were randomized within the first 30 days of the
outpatient treatment episode; and 4) had planned a treat-
ment episode of 3 months or more. Patients were ineli-
gible for the study if they: 1) were undergoing opioid
treatment or were receiving opioid substitution pharma-
cotherapy; 2) were planning to move out of the area
within 90 days; 3) were not able to provide informed con-
sent; and 4) did not speak English. Of the 507 randomized
to the study, 13 participants were excluded from the
current analyses; specifically, 10 were excluded because
their primary substance of abuse was not one of those an-
alyzed here (i.e., nine benzodiazepine and one PCP), and
three (two marijuana and one stimulant) were excludedbecause of missing baseline urine test data [22]. This study
was approved by and conducted in accordance with the
standards of the institutional review board of each partici-
pating treatment program. Review Boards included those
from: New York State Psychiatric Institute, University of
Miami, University of Washington, John Hopkins Medi-
cine, Bio-Med IRB, UT Southwestern Medical Center,
University of Cincinnati, Yale University, Long Island
Jewish Medical Center, McLean Hospital, and Oregon
Health & Science University.
Baseline assessment procedures
Baseline assessments were conducted by trained research
staff members at the treatment programs. The mean time
between treatment entry and baseline assessment was
9 days (SD = 7.1 days), with no significant differences by
primary drug class or drug use status at baseline. The base-
line assessment took approximately 2 hours to complete.
Measures
Demographic variables
The demographic variables captured were gender, age,
race/ethnicity, education, marital status, employment sta-
tus, and whether the current treatment episode was man-
dated by the criminal-justice system.
Substance use
Substance abuse and dependence were assessed using the
DSM-IV Checklist, a semi-structured interview that pro-
vides current (past year) diagnosis for substance use disor-
ders based on DSM-IV criteria [23]. Patients also were
asked to report their primary substance of abuse (i.e., the
substance of primary concern for which treatment was
sought) and to report other substances used in the prior
12 months. Frequency of use of each substance mentioned
was assessed over the 90 days prior to baseline using the
Timeline Follow-back (TLFB) tool [24], and data were sum-
marized for self-reported use in the past 7 and past 30 days.
12-step attendance
Participants were asked whether or not they had attended
any 12-step groups or meetings in the 90 days prior to
baseline assessment and if so, how many days they had
attended.
Physical and mental health
Physical health was assessed using a visual analogue scale
from the Euro Quality of Life Scale-EQ5D [25]. Scores on
this instrument range from 0 to 100, with higher scores
representing better health. Mental health was assessed
using the Patient Health Questionnaire (PHQ), which re-
sults in probable diagnoses across six psychiatric disorders
including: major depression, generalized anxiety, and
panic disorders [26].
Table 1 Baseline participant characteristics (N = 494)
Characteristic %
Female 38%
Agea 35 (11)
Race 52%
White
African American 22%
Hispanic Latino 11%
Other 15%
Education 23%
Less than High School
High School/GED 61%
More than High School 15%
Marital Status 60%
Single, Never Married
Married/Remarried 14%
Divorced/Separated/Widowed 26%
Employed 41%
Insured 76%
CJ Tx Status
No 65%
Mandated 21%
Referred or Recommend to Tx 14%
aMean years and SD.
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Social functioning was assessed using the Social Adjust-
ment Scale [27]. This 54-item instrument assesses social
role functioning in the domains of work, social and leisure
activities, family relationship, marital relationship, parental
role, and role within the family unit. Items are rated on a
5-point scale, with lower numbers indicating higher
functioning.
Statistical methods
Participants (N = 494) were divided into four categories
based on their self-reported primary drug of abuse: alcohol
(n = 104), marijuana (n = 112), cocaine/stimulants (n = 170)
and opioids (n = 108). Initial drug use status was based on
results of study intake urine tests (positive versus negative)
for the primary substance. Positive urine tests for secondary
drugs were recorded but ignored for purposes of participant
classification. In the case of those seeking treatment for al-
cohol, classification was based on self-report of any alcohol
use (yes or no) during the 7 days prior to baseline, due to
the very short detection window of breath alcohol testing
that resulted in a low frequency of positive Breathalyzer re-
sults at baseline (n = 3) among primary alcohol users.
Chi-square tests for categorical variables and t-tests for
continuous variables were employed to analyze the data as
a function of drug use status at study entry and primary
drug category using SAS 9.2 [28]. Pair-wise comparisons
were conducted between positive versus negative partici-
pants within each primary substance subgroup.
Results
Demographic characteristics
Table 1 shows baseline demographic variables for the
overall study sample (N = 494). Data is collapsed across
primary drug use and baseline positive/negative categories
because no differences were found on any demographic
variable shown for drug-positive versus -negative partici-
pants within each primary drug category or within the
drug-positive versus -negative samples overall. The one
exception was for race in the overall sample, in which
those testing positive (26.7% African American; 15.1%
Hispanic) were more likely than those testing negative
(19.6% African American; 8.7% Hispanic) to be from an
ethnic minority group (p < .05 and; p < .01).
Baseline positive/negative drug use status
Table 2 shows rates of participants abstinent by urine
test results for their primary drug, as well as rates self-
reporting any use of that drug in the previous 30 days.
Rate of participants classified as abstinent by negative
urine test at study start was 84% for primary opioid users,
76% for stimulant users, 62% for those claiming alcohol as
their primary drug (by self-report of use in past 7 days),
and 33% for primary marijuana users. Self-report of anyuse in the past 30 days was highly congruent with urine
test results for those testing drug-positive. Among those
testing drug-negative, however, 62-81% across the primary
drug categories reported having used their primary drug
within the past 30 days. Chi-square tests indicated that
rates of self-reported use versus negative urine test re-
sults were significantly discrepant for all primary drug
categories.
More detailed data about recent drug use can be de-
rived from days of self-reported drug use in the past
30 days. Across all primary drug categories, those classi-
fied as positive at baseline for their primary drug re-
ported more days of use of that primary drug in the past
30 days than did those classified as negative (results not
shown). Days of use for those testing positive versus
negative were 10.9 versus 5.5 for primary alcohol users
(t = 3.70; p < .001), 18.1 versus 7.1 for primary marijuana
users (t = 5.74; p < .001), 12.4 versus 3.6 for primary
stimulant users (t = 5.80; p < .001), and 9.7 versus 4.8 for
primary opioid users (t = 2.79; p < .01).
A different perspective on drug use status is provided
by patterns of past year substance abuse or dependence,
as shown in Table 3. Percent of participants meeting cri-
teria for abuse or dependence on their primary drug was
95-100% across all primary drug categories except
Table 2 Urine/breath baseline use status
Self-report drug use in previous 30 days
No Yes χ2 df p
Drug Urine drug-positive % (n) % (n)
Alcohoa No 35.9 (23) 64.06 (41) 18.5 1 <.001
Yes 0 (0) 100 (40)
Marijuana No 18.9 (7) 81.1 (30) 11.6 1 <.001
Yes 1.3 (1) 98.7 (74)
Cocaine/Stimulants No 31.0 (40) 68.0 (89) 13.9 1 <.001
Yes 2.4 (1) 97.6 (40)
Opioids No 37.4 (34) 62.2 (57) 9.3 1 <.001
Yes 0 (0) 100 (17)
aBiological validation of alcohol use based on Breathalyzer and on self-report of alcohol use in the past 7 days.
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slightly lower, at 80-90%. Importantly, rates of DSM
abuse or dependence were not significantly different for
those testing positive versus negative for their primary
drug at study start.
Secondary drug use
Table 3 also shows that the percentage of participants
meeting criteria for past year abuse or dependence on
non-primary drugs, which was common. Consistent with
study entry criteria, those with a primary alcohol problem
qualified at substantial rates for abuse or dependence on
other drugs (48% marijuana, 49% cocaine/stimulant, 29%
opioid; collapsed across positive/negative categories).
About half of those within every primary drug group also
met criteria for alcohol abuse or dependence. Notably, as
with abuse or dependence on the primary drug, there was
no difference in rates of abuse or dependence diagnosis
for secondary drugs among those classified as positive ver-
sus negative at baseline.Table 3 Substance abuse or dependence diagnosis and secon
Percent qu
Alcohol Marijuana
Neg
N = 64
Pos
N = 40
(χ2 [df], p) Neg
N = 37
Pos
N = 75
(χ2 [df],
Abuse/Dependence
Alcohol 95.3 100.0 (1.93 [1], 0.16) 56.7 48.0 (0.76 [1], 0
Marijuana 51.6 42.5 (0.81 [1], 0.37) 81.1 89.3 (1.45 [1], 0
Cocaine/
Stimulants
51.6 45.0 (0.42 [1], 0.51) 21.6 24.0 (0.08 [1], 0
Opioids 32.8 22.5 (1.28 [1], 0.26) 8.1 6.7 (0.08 [1], 0
Non-primary
substance
use at
baselinea
21.9 50.0 (8.85 [1], 0.003) 29.7 46.7 (2.94 [1], 0
aAlcohol use identified by self-report of any use in past 7 days; other drugs identifieTable 3 also shows the percent qualifying for active
use of a secondary drug at baseline, based on positive
urine test, or, in the case of alcohol, self-reported use
within the past 7 days. The majority of participants within
each primary drug use category did not have evidence of
active secondary drug use at the time of the baseline as-
sessment. However, with the exception of primary opioid
users, rates of active secondary drug use were higher
among those positive for their primary drug than among
those testing negative, with this difference being statisti-
cally significant for alcohol and stimulant users.
Physical health, mental health, social adjustment, and
12-step participation
As shown in Table 4, physical health status (higher scores
representing better health) was rated as worse among
those positive for marijuana (positive N = 69; negative N =
81) and cocaine/stimulants (positive N = 65; negative N =
77). Among cocaine/stimulant users, those testing positive
had lower social adjustment scores (p < .01) and higherdary use
alifying for diagnosis
Cocaine/Stimulants Opioids
p) Neg
N = 129
Pos
N = 41
(χ2 [df], p) Neg
N = 91
Pos
N = 17
(χ2 [df], p)
.38) 55.8 51.2 (1.93 [1], 0.16) 56.0 47.1 (1.93 [1], 0.16)
.23) 33.3 34.2 (0.01 [1], 0.92) 38.5 29.4 (0.50 [1], 0.48)
.80) 98.5 95.1 (1.50 [1], 0.22) 45.1 35.3 (0.56 [1], 0.46)
.78) 11.6 9.8 (0.11 [1], 0.74) 98.9 100.0 (0.19 [1], 0.66)
.09) 17.8 51.2 (18.08, <.0001) 26.4 23.5 (0.06 [1], 0.81)
d by positive urine test.
Table 4 Physical health, mental health, and social adjustment variables
Alcohol Marijuana Cocaine/Stimulants Opioids
Neg
N = 64
Pos
N = 40
(t, p) Neg
N = 37
Pos
N = 75
(t, p) Neg
N = 129
Pos
N = 41
(t, p) Neg
N = 91
Pos
N = 17
(t, p)
Physical
Healtha
74.6 67.1 (1.75, 0.08) 81.4 69.1 (3.21, p < .01) 76.6 64.7 (3.45, <0.001) 73.0 67.1 (1.20, 0.23)
Social
Adjustmentb
2.2 2.3 (1.51, 0.13) 2.0 2.1 (0.51, 0.61) 2.2 2.5 (3.37, <0.01) 2.1 2.3 (1.57, 0.14)
(χ2 [df], p) (χ2 [df], p) (χ2 [df], p) (χ2 [df], p)
Depressionc 21.9 30.0 (0.87 [1], 0.35) 10.8 17.3 (0.82 [1], 0.37) 16.3 46.3 (15.6 [1], <.001) 18.7 23.5 (0.21 [1], 0.64)
Anxietyc 29.7 20.0 (1.20 [1], 0.27) 29.7 28.0 (0.04 [1], 0.85) 23.3 31.7 (1.18 [1], 0.28) 31.9 35.3 (0.08 [1], 0.78)
Panicc 25.0 30.0 (0.31 [1], 0.58) 8.1 17.3 (1.72 [1], 0.19) 10.9 26.8 (6.33 [1], 0.02) 16.5 35.3 (3.24 [1], 0.07)
12-Stepd 68.8 40.0 (8.34 [1], <0.01) 29.7 17.3 (2.26 [1], 0.13) 73.6 48.8 (8.79 [1], <0.01) 76.9 64.7 (1.14 [1], 0.29)
aScores range from 0 to 100, with higher scores representing better health; means scores are shown.
bMean item score across 54 items; five-point item scales range from one (indicating higher functioning) to five (indicating lower functioning).
cPercent with probable diagnosis from Patient Health Questionnaire (PHQ).
dProportion of patients reporting attendance.
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panic disorder (positive = 27%; negative = 11%) than those
testing negative. Table 4 also shows a striking behavioral
difference among the drug-positive versus -negative sam-
ples in their utilization of 12-step programs in the 90 days
prior to baseline assessment. Twelve-step attendance was
endorsed by 69% who were abstinent from alcohol at
baseline, compared to 40% of those reporting alcohol use
in the past 7 days. Mean days of attendance for alcohol
users were 24.3 and 6.7, respectively (p <.05; not shown).
Among cocaine/stimulant users, 74% of those testing
negative at baseline reported 12-step attendance (com-
pared to 49% of those testing positive). Mean days of at-
tendance for cocaine/stimulant users were 19.1 and 13.2,
respectively (difference not significant; not shown). There
were no significant differences between positive versus
negative primary marijuana or opioid users in percentage
attending or mean days of attendance.Discussion
This study provides new data on characteristics and be-
haviors of those who are seeking treatment for substance
use and are assessed early in their treatment episode.
Data were derived from a large NIDA CTN study con-
ducted at 10 regionally diverse community treatment
programs and thus, may have a level of generalizability
for similar substance abuse treatment-seeking popula-
tions across the US. Specifically, these results provide
insight into the current drug use profiles of patients en-
tering programs and seeking treatment for alcohol, co-
caine/stimulants, marijuana, and opioids. These findings
also stand to help treatment providers better understand
the multiple health needs and challenges, as well as re-
silience behaviors, among patients who are initiating
substance abuse treatment.Early treatment abstinence and drug use
The results of this study confirm and extend previous
observations that a high proportion of stimulant abusers
test negative for their primary drug of abuse at treat-
ment entry or shortly thereafter [1,2,6,13,29,30]. Our
analysis of data from this large patient sample also sug-
gests that early treatment abstinence is fairly common
among substance users seeking treatment in community
outpatient counseling treatment programs, irrespective
of the primary endorsed drug of abuse, including those
who identify primary problems with opioids, cocaine/
stimulants, marijuana, and alcohol. This study also dem-
onstrates the discrepant data that emerge when drug use
status is based on different assessment methods and
timeframes. Urine testing at treatment entry provides
insight only into very recent use, versus abstinence, and
does not capture use within the past 30 days, a com-
monly assessed timeframe and one that yields higher
prevalence of recent drug use (Table 2). It is clear from
previous research in the field that, for stimulant users,
the urine test result provides important prognostic infor-
mation [1,2,6,13,29,30]; whether this is true for other
drugs of abuse remains to be seen. Also of interest for
future research is whether self-report adds any prognos-
tic value to the urine test results, and if so, what time-
frame might be important. One recommendation for
future research and clinical practice is to obtain more
detailed information about patterns of pre-treatment
drug use [17,18], which can be obtained using validated
TLFB methods [24].
This study also demonstrates important similarities
across primary substances of abuse in characteristics of
those testing positive versus negative for their primary
drug early in treatment. In particular, there was no dis-
tinction across these groups in the DSM classification of
past year abuse or dependence (Table 3). This suggests
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ing patients at intake with regard to their characteristics
or behaviors. However, assessment of current rather than
past year dependence may provide data more congruent
with behavior at the start of treatment.
Co-occurring problems
The study adds to the existing literature by identifying a
profile of adverse physical, mental health, and behavioral
characteristics associated with active versus inactive early
treatment substance use. Specifically, we found poorer
physical health status (marijuana and cocaine/stimulant
users) and poorer mental health and social adjustment
scores, with evidence of elevated rates of depression and
panic disorder, among cocaine/stimulant users testing posi-
tive for their primary drug early in treatment (Table 4).
Thus, evidence of active drug use early in treatment indi-
cates a higher likelihood of, and may be a marker for, con-
current health/mental health, and/or social adjustment
problems. This need is relevant to current thinking about
the integration of primary and mental health care within
drug and alcohol treatment settings (or vice versa) [19], a
model from which patients with active substance use and
co-morbid physical and/or mental health conditions could
greatly benefit. Given the higher likelihood of co-occurring
health and mental health problems for those with active
use, it will be important for providers to attend to drug use
behavior at, and shortly after, treatment entry and to
broaden assessments for those testing positive to include
additional health and mental health domains in anticipa-
tion of possible health and mental health care needs of
these patients.
Early treatment help-seeking
This study provides new data about the resilience of
those who test drug-negative early in treatment by show-
ing that many participants are already attending 12-step
programming prior to treatment entry, especially for pri-
mary alcohol and stimulant users. In specific terms, a
substantial percentage of alcohol (69%) and stimulant
(74%) abusers who had stopped using their primary drug
by the early treatment assessment reported recent in-
volvement in 12-step programs. Mean days of 12-step
program attendance in the past 90 days among negative
stimulant and alcohol users suggests that self-help treat-
ment may have been underway for some time before the
formal treatment program had begun. Such proactive
behavior represents an important strength that these in-
dividuals bring to the current treatment episode [31-33].
Limitations
The main limitation of the study is that individuals in-
cluded in the analysis all had agreed to participate in a re-
search study and were limited to those (including thoseendorsing alcohol as their primary drug) who reported
some drug use within the past 30 days. The sample thus
may not be fully representative of all individuals who
abuse substances and seek treatment. However, given the
WEB-TX all-comers sample was recruited from regionally
diverse settings across the US, this study may better repre-
sent seekers of treatment than other samples that have re-
cruited more narrowly focused populations. This study
was also limited in that the baseline assessment was con-
ducted after treatment entry and thus cannot differentiate
between pre-treatment and early treatment behavior
change. Future research that examines baseline-use status
should make efforts to distinguish between pre- and early
treatment behaviors. Finally, while this paper has primarily
focused on creating a greater understanding in the field of
the health and behavior characteristics of patients with
and without active use of their primary drug at treatment
entry, an important aspect of these data is their possible
prognostic capability. Future research should examine the
influence of baseline abstinence on substance use out-
comes within each of the primary drug use groups, as well
as the prognostic contribution of other health and behav-
ior variables associated with active drug use at entry.
Results of such analyses will be a useful addition to those
presented herein.
Conclusions
Our study demonstrates that early treatment abstinence is
common among substance users entering treatment with
a range of primary substances of abuse including alcohol,
marijuana, cocaine/stimulants, and opioids. The study fur-
ther demonstrates that those who are drug-negative early
in treatment are more likely to be attending 12-step pro-
gramming, while those positive at treatment entry are
more likely to have secondary drug use, as well as co-
morbid physical and mental health problems. These find-
ings provide important information for clinicians to better
understand the health issues and substance use profiles
among patients seeking treatment and to take a proactive
approach to interdisciplinary treatment needs of patients.
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